While the FDA has approved use of the 4 assay systems as complementary diagnostics in some tumor types (eg, PD-L1 IHC 28–8 pharmDx with nivolumab for HNSCC and UC), the European Medicines Agency does not recognize complementary diagnostic assays for use with immune checkpoint inhibitors. Here, CD274 is linked to head and neck squamous cell carcinoma.